Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study

Inclusion Criteria: * Age ≥ 18 years old * Patient with laboratory-confirmed SARS-CoV-2 infection as determined by PCR \< 96 h (at initial diagnosis or persistent carriage \<96 h) * Hospitalized patient with COVID-19 requiring oxygen therapy And targeting in phase B : * Patients under oxygen therapy such as nasal cannula/mask or non-invasive ventilation with paO2/FiO2 \> 200 mmHg. * Patients hospitalized for less than 7 days. * Patients with symptoms for less than 10 days or RT-PCR (\<96h) with Cycle Treshold \< 25. * Social security coverage * signed informed consent (by patient or their legally authorized representative) Exclusion Criteria: * Hypersensitivity to natural or recombinant interferon-ß * Hypersensitivity to human albumin or mannitol * Recent suicide attempt * Decompensation of liver failure * age \< 18 years * Pregnant or nursing. * Patients managed on an outpatient basis (i.e. not initially hospitalized). * Parenteral IFN treatment. In periode B, addition of new exclusion criteria * Patients with kidney transplant * Immunocompromised patients * Patients with severe systemic disease constantly threatening their vital prognosis (ASA ≥ IV: e.g. severe ARF, advanced cancer pathology, recent myocardial IDM, severe valvular dysfunction, dependence on parenteral nutrition on central line, shock, sepsis, trauma, ...). * Patients in septic shock. * Patients with documented fungal infection. * Patients on mechanical ventilation. * Patients hospitalized for COVID-19 for more than 7 days.